Payment overview · 2025
General Payments
$704.56
29 reported records · 8 companies
Healthcare provider profile · identity verified
Li Lu, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1770883787
Verified facts
What the public records show
CMS Open Payments records show Li Lu, M.D. received $704.56 in general payments during 2025 across 29 reported records.
Gilead Sciences, Inc. accounted for 31.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Trelegy Ellipta, Vemlidy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $224.73 | 31.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $210.27 | 29.8% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.77 | 13.9% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $66.70 | 9.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $50.53 | 7.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.25 | 2.9% | 1 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $17.29 | 2.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.02 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $704.56 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $166.45 | 8 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $79.96 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $79.96 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $66.70 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $50.53 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $50.53 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $43.82 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 71 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 18 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 | exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
71 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
158 | 61 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 645 | 302 |
| Losartan Potassium | Losartan Potassium | 460 | 206 |
| Donepezil Hcl | Donepezil Hcl | 409 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 297 | 148 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 130 |
| Metformin Hcl | Metformin Hcl | 248 | 105 |
| Fluticasone Propionate | Fluticasone Propionate | 207 | 103 |
| Alendronate Sodium | Alendronate Sodium | 193 | 91 |
| Diclofenac Epolamine | Diclofenac Epolamine | 185 | 83 |
| Mirtazapine | Mirtazapine | 182 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 83 |
| Jardiance | Empagliflozin | 158 | 61 |
| Omeprazole | Omeprazole | 145 | 87 |
| Diclofenac Sodium | Diclofenac Sodium | 140 | 86 |
| Gabapentin | Gabapentin | 126 | 65 |
| Meloxicam | Meloxicam | 114 | 82 |
| Azelastine Hcl | Azelastine Hcl | 110 | 60 |
| Glipizide Er | Glipizide | 108 | 43 |
| Meclizine Hcl | Meclizine Hcl | 107 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 103 | 40 |
| Simvastatin | Simvastatin | 99 | 43 |
| Famotidine | Famotidine | 98 | 77 |
| Finasteride | Finasteride | 98 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 45 |
| Ammonium Lactate | Ammonium Lactate | 92 | 72 |
| Lidocaine | Lidocaine | 79 | 38 |
| Farxiga | Dapagliflozin Propanediol | 71 | 31 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 71 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 34 |
| Trazodone Hcl | Trazodone Hcl | 66 | 37 |
| Vascepa | Icosapent Ethyl | 64 | 28 |
| Montelukast Sodium | Montelukast Sodium | 63 | 21 |
| Hydrocortisone | Hydrocortisone | 62 | 42 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 31 |
| Tradjenta | Linagliptin | 60 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 38 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 56 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | 30 |
| Xarelto | Rivaroxaban | 51 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 31 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 47 | 24 |
| Azithromycin | Azithromycin | 46 | 46 |
| Allopurinol | Allopurinol | 45 | 17 |
| Eliquis | Apixaban | 45 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 23 |
| Naproxen | Naproxen | 42 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 32 |
| Clotrimazole | Clotrimazole | 39 | 23 |
| Prolia | Denosumab | 38 | 36 |
| Rybelsus | Semaglutide | 38 | suppressed |
| Carvedilol | Carvedilol | 37 | 20 |
| Synjardy | Empagliflozin/Metformin Hcl | 35 | 13 |
| Januvia | Sitagliptin Phosphate | 34 | 13 |
| Nitroglycerin | Nitroglycerin | 34 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | 14 |
| Mupirocin | Mupirocin | 31 | 23 |
| Ketoconazole | Ketoconazole | 30 | 24 |
| Mometasone Furoate | Mometasone Furoate | 30 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | 11 |
| Loperamide | Loperamide Hcl | 28 | 27 |
| Nateglinide | Nateglinide | 28 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 28 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | 13 |
| Metformin Hcl Er | Metformin Hcl | 27 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 14 |
| Fenofibrate | Fenofibrate,micronized | 26 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 25 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 22 |
| Fluocinonide | Fluocinonide | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | 18 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Acarbose | Acarbose | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 17 |
| Celecoxib | Celecoxib | 18 | 13 |
| Linzess | Linaclotide | 18 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Baclofen | Baclofen | 16 | 11 |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | 15 |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | 11 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Furosemide | Furosemide | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | 11 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Lisinopril | Lisinopril | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $704.56 · 29 records | Gilead Sciences, Inc. | AIRSUPRA, CAPVAXIVE, CREON, Cologuard Collection Kit, FARXIGA, GARDASIL 9, KISUNLA, LINZESS, QULIPTA, TRELEGY ELLIPTA, UBRELVY, Vemlidy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error